Anastrozole is used off-label in males to lower estrogen levels, most commonly alongside testosterone replacement therapy, to treat male infertility, or to address breast tissue enlargement. The drug was originally approved by the FDA exclusively for breast cancer in postmenopausal women, and its label explicitly states it is not intended for men or children. Despite this, doctors prescribe it to men in specific hormonal situations where estrogen levels climb too high relative to testosterone.
How Anastrozole Works in Men
Men produce estrogen, specifically estradiol, through an enzyme called aromatase that converts testosterone into estradiol. This is a normal process, and men need some estradiol for bone health, brain function, and cardiovascular protection. Problems arise when aromatase activity is too high, tipping the balance toward excess estrogen.
Anastrozole blocks aromatase by binding to part of the enzyme’s active site. In men, third-generation aromatase inhibitors like anastrozole reduce the ratio of estradiol to testosterone by roughly 77%. The result: testosterone levels rise (because less is being converted) and estradiol drops. This dual shift is the reason the drug has found so many off-label uses in male health.
Managing Estrogen During Testosterone Therapy
The most common reason men take anastrozole is to control estrogen that climbs during testosterone replacement therapy. When you receive exogenous testosterone, your body’s aromatase enzyme has more raw material to convert, which can push estradiol well above normal. Elevated estradiol in men is linked to breast tenderness, swelling of breast tissue (gynecomastia), water retention, and reduced libido.
Clinicians typically consider anastrozole when estradiol levels exceed 60 pg/mL regardless of symptoms, or when levels sit between 40 and 60 pg/mL and a man reports symptoms like nipple tenderness or mood changes. A common protocol is 0.5 mg taken three times per week, though dosing varies based on individual lab work. The goal is not to eliminate estradiol entirely but to bring it into a balanced range relative to testosterone. Research on fertile men has established a testosterone-to-estradiol ratio of about 10:1 as the 20th percentile benchmark, meaning ratios below that may signal excess estrogen activity.
Preserving Fertility in Hypogonadal Men
Standard testosterone replacement shuts down the brain’s signaling to the testes, which suppresses sperm production. For men with low testosterone who still want to father children, this creates a dilemma. Anastrozole offers an alternative approach: by blocking estrogen conversion, it tricks the brain into ramping up its own testosterone-stimulating signals, boosting testosterone without introducing external hormones that would shut down sperm production.
A study of subfertile men with a BMI of 25 or higher found meaningful improvements after anastrozole treatment. Sperm concentration nearly doubled, rising from 7.8 million per milliliter to 14.2 million. Total motile sperm count increased from 12.6 million to 17.7 million. Even strict morphology, a measure of sperm shape, showed a modest but statistically significant improvement. The typical dose studied for male infertility is 1 mg daily, used in men whose lab work shows an abnormal testosterone-to-estradiol ratio suggesting excess aromatase activity.
Gynecomastia
Because anastrozole lowers estrogen, it seems like a logical treatment for gynecomastia, the growth of glandular breast tissue in males. In practice, the evidence is mixed. A randomized, placebo-controlled trial of 80 boys aged 11 to 18 with pubertal gynecomastia tested 1 mg of anastrozole daily for six months. While the drug dramatically shifted the testosterone-to-estradiol ratio (a 166% increase compared to 39% with placebo), actual breast volume reduction was not significantly different between the two groups. About 38.5% of boys on anastrozole saw a 50% or greater reduction in breast volume, compared to 31.4% on placebo. That difference was not statistically meaningful.
This suggests that once breast tissue has formed, simply lowering estrogen may not be enough to reverse it. Anastrozole may be more useful for preventing gynecomastia in men starting testosterone therapy than for shrinking tissue that already exists.
Risks of Dropping Estrogen Too Low
One of the biggest concerns with anastrozole in men is overshooting the target and suppressing estradiol too aggressively. Men need estradiol for several critical functions, and driving it too low creates its own set of problems often described informally as “crashed estrogen.” Symptoms can include joint pain and stiffness, fatigue, low mood or irritability, dry skin, and a paradoxical loss of the very libido the drug was supposed to help.
Bone Density Loss
Estradiol plays a central role in maintaining bone mineral density in both sexes. Five-year data from a large clinical trial showed that anastrozole was associated with a 6.08% decrease in lumbar spine bone density and a 7.24% decrease at the total hip. While this data comes primarily from postmenopausal women, the underlying biology applies to men as well: chronically low estradiol accelerates bone loss. Men using anastrozole long-term, particularly those who are older or have other risk factors for osteoporosis, should have their bone density monitored.
Cholesterol Changes
A systematic review and meta-analysis of randomized controlled trials found that anastrozole use beyond three months was associated with a small but significant drop in HDL cholesterol (the protective type), decreasing by about 1.67 mg/dL on average. Triglycerides and LDL cholesterol were not significantly affected. The clinical impact of this small HDL shift is uncertain for short-term users, but it adds to the overall risk profile for men on prolonged treatment.
Why It Remains Off-Label
Every use of anastrozole in men is off-label. The FDA-approved prescribing information lists its indications exclusively for postmenopausal women with breast cancer, and the patient information section states directly: “Do not take ARIMIDEX if you are a man or child.” A clinical trial in adolescent boys with gynecomastia failed to demonstrate efficacy, reinforcing the FDA’s position.
Off-label does not mean unsafe or illegitimate. Doctors routinely prescribe medications off-label when clinical experience and smaller studies support the practice. But it does mean there are no large-scale, long-term trials establishing optimal doses, treatment durations, or safety profiles specifically for men. Guidelines for managing elevated estradiol in men on testosterone therapy remain limited, and dosing is often adjusted based on individual bloodwork rather than standardized protocols.
If you’re prescribed anastrozole, regular lab monitoring of estradiol, testosterone, lipids, and periodic bone density checks for long-term users is the practical reality of managing a drug that works well in men but was never formally studied or approved for them.